

51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Cannabix Technologies Inc. (the "Company")
501 - 3292 Production Way
Burnaby, BC V5A 4R4

Item 2 Date of Material Change

July 6, 2021

Item 3 News Release

The news release dated July 6, 2021 was disseminated through GlobeNewswire on July 6, 2021.

Item 4 Summary of Material Change

The Canadian Intellectual Property Office has granted patent No. 2887841 entitled, "*Cannabis Drug Detection Device*" to the Company.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

A full description of the material change is described in Item 4 above and in the attached news release which was filed on SEDAR (See Appendix A).

On June 5, 2014, the Company and Cannabix Breathalyzer Inc (a private company) entered into a definitive licensing agreement for marijuana breath detection technology. The definitive licensing agreement ("Definitive Agreement") provides the Company (the "Licensee") exclusive right, title, and interest in United States Patent Application Serial No. 61/981,650 and its foreign counterpart (Canadian Intellectual Property Office Patent Application No. 2887841) ("Licensed Patent") from Cannabix Breathalyzer Inc. (the licensor). The Definitive Agreement defines the Licensed Patent as the *claims derived from United States Patent Application Serial No. 61/981,650 and any patent issued in the future from any reissue, reexamination, divisional, continuation and/or continuation-in-part of the Licensed Patents, including any foreign counterpart thereof.*

In consideration for the Licensed Patent, the Company has completed all share and warrant payment obligations to Cannabix Breathalyzer Inc. as follows:

- Issued 7,500,000 common shares to the shareholders of Cannabix Breathalyzer Inc. and issued 7,500,000 warrants exercisable at \$0.075 (fully exercised by June 26, 2015).
- Issued 7,500,000 of common shares of the Company on April 9, 2015 triggered by the first prototype delivery to the Company.
- Issued 5,000,000 common shares of the Company on January 13, 2021 triggered by USPTO grant of patent 10,888,249 entitled, "*Cannabis Drug Detection Device*" (originally filed as provisional applications 61/981,650 and 14/689434). This was the final milestone payment by the Company in relation to the Definitive Agreement.

5.2 *Disclosure for Restructuring Transactions*

N/A

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

None

Item 8 Executive Officer

Rav Mlait, Chief Executive Officer - (604) 551-7831

Item 9 Date of Report

July 6, 2021

Schedule A

Cannabix Technologies Granted Cannabis Drug Detection Device Canadian Patent, Delivers THCBA to US Clinic

Vancouver, British Columbia, July 6, 2021 -- Cannabix Technologies Inc. (the “Company” or “Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the Canadian Intellectual Property Office (CIPO) has granted patent No. 2887841 entitled, “*Cannabis Drug Detection Device*”. The Company has been pursuing this original patent application since its filing on April 16, 2015. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of $\Delta 9$ -tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.

“Similar to our USPTO patent, the intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2015. This patent is a useful plank in our IP protection strategy” said Dr. Raj Attariwala.

The Company also reports that in June it delivered its THC Breath Analyzer (“THCBA”) to a clinic in the Northwestern, U.S. for beta testing. The collaborating clinic has a robust drug testing operation and is one of the top drug testing providers to employers within its respective state. Beta-testing of the THCBA prototype is focused on improving user and administrator experience, identifying cross-reactivity of other substances within a semi-controlled study population and to further train the device’s machine learning database and sensitivity profile. The

THCBA is a drug screening device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of THC.

“In the last several months we have seen the states of Oregon, New Jersey, New York and Arizona legalize recreational use of marijuana and several other states like Virginia, New Mexico, Montana and Connecticut have taken steps to either legalize or decriminalize cannabis possession in some way. This has led to recent reports from AAA and IIHS outlining the impact of driving performance under the influence of cannabis. Furthermore, employers are re-examining their drug testing policies, procedures and tools. There is a massive sea-change happening in the U.S. related to cannabis use and Cannabix Technologies is at the forefront of developing the tools to aid public safety and create more relevant and fairer cannabis testing technology”, stated CEO, Rav Mlait.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.